TiGenix: Notice in relation to the convertible bonds due 2018
(Thomson Reuters ONE) -
NOTICE
THIS NOTICE IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR
INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR
ANY JURISDICTION WHERE TO DO SO WOULD BE UNLAWFUL
TiGenix: notice in relation to the convertible bonds due 2018
Leuven (BELGIUM) - 13 May 2015 - TiGenix NV (Euronext Brussels: TIG; the
"Company"), an advanced biopharmaceutical company focused on developing and
commercialising novel therapeutics from its proprietary platform of allogeneic
expanded adipose-derived stem cells in inflammatory and autoimmune diseases, is
giving this notice in relation to the 9% convertible bonds due 2018 (ISIN Code:
BE6276591128) (the "Bonds") issued by the Company.
It is hereby announced that on 20 April 2015 the shareholders' meeting of the
Company acknowledged, approved and ratified the rights granted by the Company
under the terms and conditions of the Bonds, including without limitation
condition 6.2(j), condition 6.7 and condition 7.5 in accordance with article
556 of the Companies Code.
For more information:
Claudia D'Augusta
Chief Financial Officer
T: +34 91 804 92 64
Claudia.daugusta(at)tigenix.com
About TiGenix
TiGenix NV (Euronext Brussels: TIG) is an advanced biopharmaceutical company
focused on developing and commercialising novel therapeutics from its
proprietary platform of allogeneic, or donor-derived, expanded adipose-derived
stem cells, known as eASCs, in inflammatory and autoimmune diseases. Two
products from this technology platform are currently in clinical development.
Cx601 is in Phase 3 for the treatment of complex perianal fistulas in Crohn's
disease patients. Cx611 is in Phase 2b for early rheumatoid arthritis, and in
Phase 1b for severe sepsis. TiGenix also developed ChondroCelect, an autologous
cell therapy product for cartilage repair of the knee, which was the first
Advanced Therapy Medicinal Product (ATMP) to be approved by the European
Medicines Agency (EMA). From June 2014, the marketing and distribution rights of
ChondroCelect have been exclusively licensed to Sobi for the European Union
(except for Finland, where it is distributed by the Finnish Red Cross Blood
Service), Norway, Russia, Switzerland and Turkey, and the countries of the
Middle East and North Africa. TiGenix is headquartered in Leuven (Belgium) and
has operations in Madrid (Spain). For more information, please visit
www.tigenix.com.
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: TiGenix via GlobeNewswire
[HUG#1921340]
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="Klondex Reports 2015 Q1 Net Income of $10.1 Million or $0.08 per shareDatum: 13.05.2015 - 19:01 Uhr
Sprache: Deutsch
News-ID 393116
Anzahl Zeichen: 3467
contact information:
Town:
Leuven
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 210 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"TiGenix: Notice in relation to the convertible bonds due 2018"
steht unter der journalistisch-redaktionellen Verantwortung von
TiGenix (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
